EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Extreme bradycardia in BRASH syndrome unmasked by severe amiodarone-induced hypothyroidism

Julien Kasambi Bayanda

European Journal of Case Reports in Internal Medicine · 26.10.2026 · 13 (11)

DOI: 10.12890/2026_007298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Case Reports in Internal Medicine, online erschienen am 26.10.2026. Verfasst von Julien Kasambi Bayanda. Beteiligte Einrichtung: Faculty of Medicine, Université Évangélique en Afrique (UEA), Bukavu, Democratic Republic of the Congo. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

BRASH syndrome – bradycardia, renal failure, AV nodal blockade, shock and hyperkalaemia – is a self-amplifying pathophysiological loop. Its association with severe amiodarone-induced hypothyroidism is rarely described in detail. Case description: A 79-year-old woman with permanent atrial fibrillation on long-term amiodarone and bisoprolol presented after prolonged unwitnessed floor immobilisation with extreme bradycardia (24–30 bpm), haemodynamic instability, KDIGO stage 3 acute kidney injury, hyperkalaemia (5.5 mmol/l), metabolic acidosis, rhabdomyolysis and profound hypothyroidism (TSH 68.5 mUI/l; free T4 4.62 pmol/l) against a normal thyroid baseline 13 months prior. The Popoveniuc myxoedema coma score was 45 (high-risk zone). High-sensitivity troponin T showed flat kinetics consistent with type 2 myocardial injury. Isoproterenol was required for bradycardia refractory to initial metabolic correction, achieving a ventricular rate of 62–68 bpm with QTc shortening from 0.62 s to 0.38 s. The patient was discharged on day 8 with renal recovery and improving thyroid function. Thyroid antibody negativity at 30-day follow-up was consistent with an amiodarone-induced rather than autoimmune aetiology.

Conclusion

This case illustrates BRASH syndrome presenting with only mild hyperkalaemia in the context of severe amiodarone-induced hypothyroidism, which may have potentiated the pathophysiological loop. Systematic thyroid monitoring during long-term amiodarone therapy and multi-target metabolic correction, including isoproterenol as a pharmacological bridge, may avert invasive pacing.

Schlagwörter

Stichwörter der Autor:innen

BRASH syndromeamiodaronebradycardiahypothyroidismisoproterenol

Autor:innen und Institutionen

  • Faculty of Medicine, Université Évangélique en Afrique (UEA), Bukavu, Democratic Republic of the Congo.
  • Department of Internal Medicine, Emergency and Critical Care, Panzi General Referral Hospital, Bukavu, Democratic Republic of the Congo.
  • Emergency and Critical Care Medicine, Centre Hospitalier Nord Deux-Sèvres (CHNDS), Faye-l'Abbesse, France.

Zitieren

APA

Kasambi Bayanda, J. (2026). Extreme bradycardia in BRASH syndrome unmasked by severe amiodarone-induced hypothyroidism. European Journal of Case Reports in Internal Medicine, 13(11). https://doi.org/10.12890/2026_007298

Vancouver

Kasambi Bayanda J. Extreme bradycardia in BRASH syndrome unmasked by severe amiodarone-induced hypothyroidism. European Journal of Case Reports in Internal Medicine. 2026;13(11). doi:10.12890/2026_007298

BibTeX
@article{KasambiBayanda2026,
  author = {Kasambi Bayanda, Julien},
  title = {Extreme bradycardia in BRASH syndrome unmasked by severe amiodarone-induced hypothyroidism},
  journal = {European Journal of Case Reports in Internal Medicine},
  year = {2026},
  volume = {13},
  number = {11},
  doi = {10.12890/2026_007298}
}
Kostenlos starten →